{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:35:53Z","timestamp":1787027753415,"version":"build-2736575974"},"reference-count":57,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T00:00:00Z","timestamp":1661126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The objective of our paper was to answer the following question: how do patients with HPV-related oropharyngeal squamous cell carcinoma OPSCC (Population) enrolled in clinical trials (Intervention), compared with national database reports of HPV-associated OPSCC patients (Comparison), present demographically (Outcome)? We conducted a systematic review and meta-analysis of studies pertaining to clinical trials of HPV-associated OPSCC and participant demographics in the United States. PubMed, Scopus, CINAHL, and the Cochrane Library were searched from inception to 2 February 2022. Studies of overlapping participant cohorts and\/or studies conducted outside of the United States were excluded. Primary outcomes were patient age, sex, and race. Secondary outcomes were smoking history, alcohol history, history of prior cancer, and tumor origin site. Meta-analysis of single means (mean, N for each study, and standard deviation) for age, pack years, and smoking years was performed. Pooled prevalence rates of gender, race, alcohol history, tobacco history, and tumor origin site were expressed as a percentage, with 95% confidence intervals. Meta-analysis found patients to be predominately non-smoking white males, with tumors originating from the tonsil. Our findings reflected the demographics reported by the National Cancer Database (NCDB) for HPV-associated OPSCC. This indicates that HPV-associated OPSCC patients are appropriately represented in clinical trial demographics.<\/jats:p>","DOI":"10.3390\/cancers14164061","type":"journal-article","created":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T21:30:34Z","timestamp":1661203834000},"page":"4061","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis of Clinical Trial Demographics"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1573-8257","authenticated-orcid":false,"given":"Tamar M.","family":"Gordis","sequence":"first","affiliation":[{"name":"Department of Otolaryngology\u2014Head and Neck Surgery, Medical University of South Carolina, Charleston, SC 29425, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua L.","family":"Cagle","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2014Head and Neck Surgery, Medical University of South Carolina, Charleston, SC 29425, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun A.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2014Head and Neck Surgery, Medical University of South Carolina, Charleston, SC 29425, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason G.","family":"Newman","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2014Head and Neck Surgery, Medical University of South Carolina, Charleston, SC 29425, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"103243","DOI":"10.1016\/j.critrevonc.2021.103243","article-title":"Decreasing treatment burden in HPV-related OPSCC: A systematic review of clinical trials","volume":"160","author":"Iorio","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1200\/JCO.19.00370","article-title":"Evolution of the oropharynx cancer epidemic in the United States: Moderation of increasing incidence in younger individuals and shift in the burden to older individuals","volume":"37","author":"Tota","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.otc.2012.04.002","article-title":"Impact of HPV-related head and neck cancer in clinical trials: Opportunity to translate scientific insight into personalized care","volume":"45","author":"Chung","year":"2012","journal-title":"Otolaryngol. Clin. N. Am."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.ijrobp.2019.12.015","article-title":"Four influential clinical trials in human papilloma virus-associated oropharynx cancer","volume":"106","author":"Margalit","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1001\/archinte.162.15.1682","article-title":"Representation of the elderly, women, and minorities in heart failure clinical trials","volume":"162","author":"Heiat","year":"2002","journal-title":"Arch Intern. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1089\/aid.2014.0205","article-title":"Sex, age, race and intervention type in clinical studies of HIV cure: A systematic review","volume":"31","author":"Johnston","year":"2015","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e205202","DOI":"10.1001\/jamanetworkopen.2020.5202","article-title":"Participation of women and older participants in randomized clinical trials of lipid-lowering therapies: A systematic review","volume":"3","author":"Khan","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e1914745","DOI":"10.1001\/jamanetworkopen.2019.14745","article-title":"Demographic characteristics of participants in rheumatoid arthritis randomized clinical trials: A systematic review","volume":"2","author":"Strait","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1214\/aoms\/1177729756","article-title":"Transformations related to the angular and the square root","volume":"21","author":"Freeman","year":"1950","journal-title":"Ann. Math. Statist."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0895-4356(01)00377-8","article-title":"Funnel plots for detecting bias in meta-analysis: Guidelines on choice of axis","volume":"54","author":"Sterne","year":"2001","journal-title":"J. Clin. Epidemiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1158\/1078-0432.CCR-18-1763","article-title":"Immunotherapy Targeting HPV16\/18 Generates Potent Immune Responses in HPV-Associated Head and Neck CancerDNA Immunotherapy in HPV-Associated Head and Neck Cancer","volume":"25","author":"Aggarwal","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.oraloncology.2015.05.007","article-title":"Biologic predictors of serologic responses to HPV in oropharyngeal cancer: The HOTSPOT study","volume":"51","author":"Anderson","year":"2015","journal-title":"Oral Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa0912217","article-title":"Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer","volume":"363","author":"Ang","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S1470-2045(17)30246-2","article-title":"Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: A single-arm, phase 2 study","volume":"18","author":"Chen","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.ijrobp.2015.08.033","article-title":"Phase 2 trial of de-intensified chemoradiation therapy for favorable-risk human papillomavirus\u2013associated oropharyngeal squamous cell carcinoma","volume":"93","author":"Chera","year":"2015","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1002\/nbm.3412","article-title":"Intravoxel incoherent motion imaging kinetics during chemoradiotherapy for human papillomavirus-associated squamous cell carcinoma of the oropharynx: Preliminary results from a prospective pilot study","volume":"28","author":"Ding","year":"2015","journal-title":"NMR Biomed."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/hed.24938","article-title":"Phase I study of induction chemotherapy with afatinib, ribavirin, and weekly carboplatin and paclitaxel for stage IVA\/IVB human papillomavirus-associated oropharyngeal squamous cell cancer","volume":"40","author":"Dunn","year":"2018","journal-title":"Head Neck"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/jnci\/djn011","article-title":"Improved Survival of Patients with Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma in a Prospective Clinical Trial","volume":"100","author":"Fakhry","year":"2008","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1200\/JCO.2014.55.1937","article-title":"Human Papillomavirus and Overall Survival After Progression of Oropharyngeal Squamous Cell Carcinoma","volume":"32","author":"Fakhry","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.ijrobp.2020.04.014","article-title":"Dose and Volume De-Escalation for Human Papillomavirus\u2013Positive Oropharyngeal Cancer is Associated with Favorable Posttreatment Functional Outcomes","volume":"107","author":"Foster","year":"2020","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(18)32779-X","article-title":"Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): A randomised, multicentre, non-inferiority trial","volume":"393","author":"Gillison","year":"2019","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1200\/JCO.2007.12.7662","article-title":"EGFR, p16, HPV Titer, Bcl-xL and p53, Sex, and Smoking as Indicators of Response to Therapy and Survival in Oropharyngeal Cancer","volume":"26","author":"Kumar","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1200\/JCO.2016.68.3300","article-title":"E1308: Phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx\u2014ECOG-ACRIN Cancer Research Group","volume":"35","author":"Marur","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/jamaoncol.2018.4051","article-title":"Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16\u2013related cancer: A phase 2 clinical trial","volume":"5","author":"Massarelli","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/onco.13742","article-title":"De-escalated adjuvant therapy after transoral robotic surgery for human papillomavirus-related oropharyngeal carcinoma: The Sinai robotic surgery (SIRS) trial","volume":"26","author":"Miles","year":"2021","journal-title":"Oncologist"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.oraloncology.2019.06.021","article-title":"Standard of care vs reduced-dose chemoradiation after induction chemotherapy in HPV+ oropharyngeal carcinoma patients: The Quarterback trial","volume":"95","author":"Misiukiewicz","year":"2019","journal-title":"Oral Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.ijrobp.2020.08.029","article-title":"Early 18F-FDG-PET Response During Radiation Therapy for HPV-Related Oropharyngeal Cancer May Predict Disease Recurrence","volume":"108","author":"Mowery","year":"2020","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"105164","DOI":"10.1016\/j.oraloncology.2020.105164","article-title":"Palbociclib and cetuximab in cetuximab-resistant human papillomavirus-related oropharynx squamous-cell carcinoma: A multicenter phase 2 trial","volume":"114","author":"Oppelt","year":"2021","journal-title":"Oral Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"105566","DOI":"10.1016\/j.oraloncology.2021.105566","article-title":"Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience","volume":"122","author":"Rosenberg","year":"2021","journal-title":"Oral Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1200\/JCO.2015.62.5970","article-title":"Association of Human Papillomavirus and p16 Status with Outcomes in the IMCL-9815 Phase III Registration Trial for Patients with Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated with Radiotherapy with or without Cetuximab","volume":"34","author":"Rosenthal","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.oraloncology.2015.12.001","article-title":"Comparisons of dysphagia and quality of life (QOL) in comparable patients with HPV-positive oropharyngeal cancer receiving chemo-irradiation or cetuximab-irradiation","volume":"54","author":"Samuels","year":"2016","journal-title":"Oral Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/annonc\/mdy522","article-title":"OPTIMA: A phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer","volume":"30","author":"Seiwert","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1158\/1940-6207.CAPR-09-0149","article-title":"Racial Survival Disparity in Head and Neck Cancer Results from Low Prevalence of Human Papillomavirus Infection in Black Oropharyngeal Cancer Patients","volume":"2","author":"Settle","year":"2009","journal-title":"Cancer Prev. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1002\/hed.25760","article-title":"Patient perspectives and treatment regret after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal cancer: Findings from a phase II trial","volume":"41","author":"Shaverdian","year":"2019","journal-title":"Head Neck"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/hed.21997","article-title":"Matted nodes: Poor prognostic marker in oropharyngeal squamous cell carcinoma independent of HPV and EGFR status","volume":"34","author":"Spector","year":"2012","journal-title":"Head Neck"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1002\/hed.26085","article-title":"Paired phase II trials evaluating cetuximab and radiotherapy for low risk HPV associated oropharyngeal cancer and locoregionally advanced squamous cell carcinoma of the head and neck in patients not eligible for cisplatin","volume":"42","author":"Swiecicki","year":"2020","journal-title":"Head Neck"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1002\/hed.22004","article-title":"inducTION of mage-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma","volume":"34","author":"Sewell","year":"2012","journal-title":"Head Neck"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1200\/JCO.20.03128","article-title":"Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002)","volume":"39","author":"Yom","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.ijrobp.2019.11.021","article-title":"A Phase 2 Trial of Alternative Volumes of Oropharyngeal Irradiation for De-intensification (AVOID): Omission of the Resected Primary Tumor Bed After Transoral Robotic Surgery for Human Papilloma Virus\u2013Related Squamous Cell Carcinoma of the Oropharynx","volume":"106","author":"Lukens","year":"2020","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/ijc.30442","article-title":"The national landscape of human papillomavirus-associated oropharynx squamous cell carcinoma","volume":"140","author":"Liederbach","year":"2017","journal-title":"Int. J. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41571-022-00603-7","article-title":"HPV-associated oropharyngeal cancer: Epidemiology, molecular biology and clinical management","volume":"19","author":"Lechner","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1097\/PAS.0b013e318253a2d1","article-title":"Validation of Methods for Oropharyngeal Cancer HPV Status Determination in US Cooperative Group Trials","volume":"36","author":"Jordan","year":"2012","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.oraloncology.2013.12.019","article-title":"Epidemiology of HPV-associated oropharyngeal cancer","volume":"50","author":"Pytynia","year":"2014","journal-title":"Oral Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1200\/JCO.2011.36.4596","article-title":"Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States","volume":"29","author":"Chaturvedi","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1177\/0194599815592157","article-title":"HPV-positive oropharyngeal carcinoma: A systematic review of treatment and prognosis","volume":"153","author":"Wang","year":"2015","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"665","DOI":"10.6004\/jnccn.2011.0055","article-title":"The Epidemic of HPV-associated oropharyngeal cancer is here: Is it time to change our treatment paradigms?","volume":"9","author":"Sturgis","year":"2011","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.2217\/fon-2020-1262","article-title":"Race and ethnicity representation in clinical trials: Findings from a literature review of Phase I oncology trials","volume":"17","author":"Camidge","year":"2021","journal-title":"Futur. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1186\/s13063-015-1023-4","article-title":"A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results","volume":"16","author":"Curtis","year":"2015","journal-title":"Trials"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e217063","DOI":"10.1001\/jamanetworkopen.2021.7063","article-title":"Reporting of study participant demographic characteristics and demographic representation in Premarketing and postmarketing studies of novel cancer therapeutics","volume":"4","author":"Varma","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_51","first-page":"S221","article-title":"Gender and Ethnic\/Racial Disparities in Health Care Utilization Among Older Adults","volume":"57","author":"Dunlop","year":"2002","journal-title":"J. Gerontol. Ser. B Psychol. Sci. Soc. Sci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.socscimed.2008.03.019","article-title":"Disparities and distrust: The implications of psychological processes for understanding racial disparities in health and health care","volume":"67","author":"Dovido","year":"2008","journal-title":"Soc. Sci. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.cpcardiol.2018.11.002","article-title":"Increasing Diversity in Clinical Trials: Overcoming Critical Barriers","volume":"44","author":"Clark","year":"2018","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/cncr.23157","article-title":"Barriers to recruiting underrepresented populations to cancer clinical trials: A systematic review","volume":"112","author":"Ford","year":"2008","journal-title":"Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/cpt.1180","article-title":"Demographic composition of select oncologic new molecular entities approved by the FDA between 2008 and 2017","volume":"104","author":"Ramamoorthy","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e191870","DOI":"10.1001\/jamaoncol.2019.1870","article-title":"Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018","volume":"5","author":"Loree","year":"2019","journal-title":"JAMA Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/16\/4061\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:13:46Z","timestamp":1760141626000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/16\/4061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,22]]},"references-count":57,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["cancers14164061"],"URL":"https:\/\/doi.org\/10.3390\/cancers14164061","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,22]]}}}